NCT01260467

Memantine for Recurrent Glioblastoma

A Phase II Study of Memantine in the Treatment of Recurrent Glioblastoma

• Status: Terminated
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 4 (actual)
• Sponsor: University of Rochester · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to determine if a medication called memantine is effective in treating glioblastoma. Memantine targets a specific receptor, called a glutamate receptor, which is thought to be involved in the growth of brain tumors. It has previously been studied for other types of conditions, such as Alzheimer's disease, but it has not yet been evaluated in the treatment of brain tumors. The investigators will also be determining how common it is for patients with brain tumors to have side effects to memantine. Memantine will be taken by mouth twice a day.

Conditions

• Glioblastoma

Interventions

Type	Name	Description
DRUG	memantine	10 milligrams orally twice a day

Timeline

• Start date: 2010-11-01
• Primary completion: 2014-04-01
• Completion: 2014-04-01
• First posted: 2010-12-15
• Last updated: 2015-12-10
• Results posted: 2015-12-10

Locations

1 site across 1 country: United States